1. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 168: 1675-82.
2. Ardiles L, Ramírez P, Moya P, Caorsi I, Mezzano S. Anticardiolipin antibodies in acute poststreptococcal glomerulonephritis and streptococcal impetigo. Nephron 1999; 83: 47-52.
3. Ardiles LG, Olavarría F, Elgueta M, Moya P, Mezzano S. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenic role. Nephron 1998; 78: 278-83.
4. Amigo MC, García T, Robles M, Bochicchio T, Reyes PA. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992; 19: 1181-5.
5. Falk RJ, Jennette JC, Nachman PH. Primary Glomerular Disease. In Brenner & Rector's The Kidney, ed Brenner BM, WB Saunders, 2000; 1284-92.
6. Mezzano S, Rojas G, Ardiles L, Caorsi I, Bertoglio JC, López MI et al. Idiopathic membranous nephropathy, associated with HLA-DRw3 and not related to monocyte-phagocyte system Fc receptor dysfunction, in father and son. Nephron 1991; 58: 320-4.
7. Couser WG, Shankland SJ. Membranous Nephropathy. In: Comprehensive Clinical Nephrology, ed Johnson RJ & Feehally J, Elsevier, 2003; 295-307.
8. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
9. Hunt J, Krilis S. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-9.
10. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60.
11. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
12. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 1991; 143: 223-9.
13. Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-6.
14. Ardiles L, Mezzano S, Arriagada A, Caorsi I. Clinical course in 51 patients with idiopathic membranous glomerulopathy. Rev Méd Chile 1989; 117: 266-72.
15. Quereda C, Otero GG, Pardo A, Orte L, Rivera M, Gonzalo A et al. Prevalence of antiphospholipid antibodies in nephropathies not due to systemic lupus erythematosus. Am J Kidney Dis 1994; 23: 555-61.
16. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 1991; 39: 1225-31.
17. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
18. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Breda-Vriesman PJ V et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:1544-7.
19. Mcneil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
20. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.